FY2017 Earnings Estimate for Amicus Therapeutics, Inc. Issued By Leerink Swann (FOLD)

Amicus Therapeutics, Inc. (NASDAQ:FOLD) – Equities research analysts at Leerink Swann increased their FY2017 EPS estimates for Amicus Therapeutics in a research report issued on Tuesday. Leerink Swann analyst J. Schwartz now expects that the biopharmaceutical company will earn ($1.76) per share for the year, up from their prior estimate of ($1.77). Leerink Swann currently has a “Outperform” rating and a $24.00 target price on the stock. Leerink Swann also issued estimates for Amicus Therapeutics’ Q4 2017 earnings at ($0.33) EPS.

Several other equities research analysts have also issued reports on FOLD. BidaskClub lowered shares of Amicus Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, December 7th. Zacks Investment Research lowered shares of Amicus Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, December 19th. Cowen reaffirmed a “buy” rating and set a $22.00 price target on shares of Amicus Therapeutics in a report on Wednesday, January 10th. ValuEngine raised shares of Amicus Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. Finally, Robert W. Baird set a $20.00 price target on shares of Amicus Therapeutics and gave the company a “buy” rating in a report on Wednesday, February 7th. Four investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $19.06.

Shares of Amicus Therapeutics (FOLD) opened at $15.68 on Thursday. The company has a current ratio of 6.32, a quick ratio of 6.22 and a debt-to-equity ratio of 0.39. Amicus Therapeutics has a 1-year low of $5.87 and a 1-year high of $17.40.

In related news, insider Jay Barth sold 20,000 shares of Amicus Therapeutics stock in a transaction that occurred on Tuesday, January 23rd. The shares were sold at an average price of $16.80, for a total transaction of $336,000.00. Following the sale, the insider now directly owns 105,409 shares in the company, valued at approximately $1,770,871.20. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO John F. Crowley sold 65,581 shares of Amicus Therapeutics stock in a transaction that occurred on Thursday, December 21st. The stock was sold at an average price of $13.51, for a total transaction of $885,999.31. Following the sale, the chief executive officer now owns 393,076 shares in the company, valued at $5,310,456.76. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 250,390 shares of company stock worth $3,620,581. 3.40% of the stock is owned by corporate insiders.

Several hedge funds and other institutional investors have recently modified their holdings of FOLD. Teachers Advisors LLC lifted its position in shares of Amicus Therapeutics by 3.2% in the 2nd quarter. Teachers Advisors LLC now owns 261,545 shares of the biopharmaceutical company’s stock worth $2,634,000 after purchasing an additional 8,046 shares during the period. TIAA CREF Investment Management LLC lifted its position in shares of Amicus Therapeutics by 12.0% in the 2nd quarter. TIAA CREF Investment Management LLC now owns 487,751 shares of the biopharmaceutical company’s stock worth $4,912,000 after purchasing an additional 52,136 shares during the period. Nationwide Fund Advisors lifted its position in shares of Amicus Therapeutics by 27.9% in the 2nd quarter. Nationwide Fund Advisors now owns 168,709 shares of the biopharmaceutical company’s stock worth $1,699,000 after purchasing an additional 36,764 shares during the period. Amalgamated Bank lifted its position in shares of Amicus Therapeutics by 5.7% in the 2nd quarter. Amalgamated Bank now owns 18,451 shares of the biopharmaceutical company’s stock worth $186,000 after purchasing an additional 1,002 shares during the period. Finally, New York State Common Retirement Fund lifted its position in shares of Amicus Therapeutics by 8.3% in the 2nd quarter. New York State Common Retirement Fund now owns 153,500 shares of the biopharmaceutical company’s stock worth $1,546,000 after purchasing an additional 11,699 shares during the period.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally posted by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2018/02/15/fy2017-earnings-estimate-for-amicus-therapeutics-inc-issued-by-leerink-swann-fold.html.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.

Earnings History and Estimates for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply